U.S. stock night market fluctuations: INDP rose 3.21% in the night market, with active capital and increased volatility; subsequent trends await observation
I'm LongbridgeAI, I can summarize articles.Indaptus Therapeutics rose 3.21% in after-hours trading; Recursion Pharmaceuticals rose 0.31% in after-hours trading, with a transaction volume of USD 19,300; Intellia Therapeutics rose 0.16% in after-hours trading, with a transaction volume of USD 7,025; Summit Therapeutics fell 6.30% in after-hours trading, with a transaction volume of USD 5,830
U.S. Stock Night Market Movements
Indaptus Therapeutics rose 3.21% in the night market, with no significant news recently. Trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.
Stocks with High Trading Volume in the Industry
Recursion Pharmaceuticals rose 0.31% in the night market. Based on recent key news:
- On June 9, Recursion Pharmaceuticals integrated AI technology into its platform, covering biology, chemistry, and clinical technology to accelerate drug discovery and development. The company has established partnerships with major pharmaceutical companies and has a diversified product line. Key clinical data will be released in the next 12-18 months, focusing on operational efficiency and risk diversification. These factors have driven the stock price up.
Significant technological advancements in drug discovery have garnered high market attention.
Intellia Therapeutics rose 0.16% in the night market, with a trading volume of $7,025 and no significant news recently. Trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.
Summit Therapeutics fell 6.30% in the night market. Based on recent key news:
-
On June 9, Summit Therapeutics announced the launch of a $500 million public offering. The company plans to use the funds for the development of its lead product candidate ivonescimab, operational funding, and general corporate purposes. This news led to a 9% drop in the stock price during after-hours trading.
-
On June 9, Summit Therapeutics' stock price fell to $13 in after-hours trading due to the company seeking equity financing. JP Morgan, Goldman Sachs, and Citigroup are acting as joint bookrunners.
-
On June 9, Summit Therapeutics launched a $500 million public offering and granted underwriters a 30-day option to purchase an additional $75 million in stock. This move aims to fund the development of its lead product candidate ivonescimab. The biopharmaceutical industry has shown volatility recently, and investors should exercise caution